Check t Section

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

nis box if no longer subject to	
16. Form 4 or Form 5	
ns may continue. See	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average bu	rden
hours per response:	0.5

obligation Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Westphal Christoph H					2. Issuer Name and Ticker or Trading Symbol Flex Pharma, Inc. [FLKS]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
	(Fii X PHARM LSTON ST	A, INC.	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 11/30/2015								X	X Officer (give title below) Other (s below) President and CEO				
(Street) BOSTON (City))2199 Zip)		- 4. If	Line) X Form filed by									n filed by Oi	roup Filing (Check Applicable One Reporting Person More than One Reporting			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			2. Transacti Date (Month/Day		Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Disposed Of				5)	Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	Price		Transac	Reported Transaction(s) (Instr. 3 and 4)			(111501. 4)	
Common Stock 11/30/2					015	15		P ⁽¹⁾		887	A	\$12.3	213	3,92	23,414		D		
Common Stock															2,69	97,264		,	By Longwood Fund II. L.P. ⁽²⁾
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise (Month/Day/Year) Price of Derivative Security 3. Transaction Date (Month/Day/Year) (Month/Day/Year)				tion Date,		ansaction of of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)				9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	or Number of Shares						

Explanation of Responses:

Remarks:

/s/ Robert Hadfield, Attorney-12/01/2015 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{1. \} The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2015.$

^{2.} Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II, L.P. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the issuer's securities held by Longwood Fund II, L.P. (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.